Viking Therapeutics, Inc. (VKTX) is trading at $25.48, down 8.83 percent or $2.47 on Tuesday, after announcing a multi-year manufacturing agreement with CordenPharma.
The stock opened at $26.26 and has traded between $24.44 and $26.38, compared to a previous close of $27.96 on the Nasdaq. Current volume stands at 4.81 million shares, slightly above the average volume of 4.41 million. The stock's 52-week range is $24.41 to $89.10.
The deal secures long-term supply of both subcutaneous and oral forms of VK2735, a drug candidate for obesity, supporting what Viking describes as a potential multi-billion-dollar annual product opportunity.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.